Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Description
INTRODUCTION: Anti-spike monoclonal antibodies (mAbs) were previously authorized for the prevention and treatment of COVID-19 in immunocompromised patients. However, they are no longer authorized in the US due to their lack of neutralizing activity
